Related Experiment Video
Updated: Jun 12, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
A new look at established therapies: practical tools for optimizing insulin use.
James R Gavin1, Virginia Peragallo-Dittko2, Philip T Rodgers3
1Healing Our Village, Inc, and Emory University School of Medicine, Atlanta, GA (Dr Gavin)
The Diabetes Educator
|June 1, 2010
Summary
Early insulin therapy for type 2 diabetes mellitus (T2DM) enhances glycemic control and beta-cell function. Structured diabetes education programs improve patient adherence and treatment outcomes when initiating or intensifying insulin regimens.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 Diabetes Mellitus (T2DM) management often requires insulin therapy.
- Current guidelines advocate for earlier insulin initiation and prompt intensification.
- Optimizing insulin regimens is crucial for achieving therapeutic goals.
Purpose of the Study:
- To review evidence supporting early insulin initiation in T2DM.
- To outline agent selection and regimen considerations for T2DM patients.
- To provide practical strategies for clinicians and diabetes educators.
Main Methods:
- Review of current evidence and clinical guidelines.
- Analysis of factors influencing insulin therapy decisions.
- Discussion of practical implementation strategies for diabetes educators and clinicians.
Main Results:
- Early insulin initiation improves glycemic control, beta-cell function, and potentially cardiovascular outcomes.
- ADA/EASD 2008 algorithm promotes earlier insulin use and intensification.
- Regimen selection depends on A1C, glucose patterns, and patient factors.
Conclusions:
- Structured diabetes education is vital for patients starting or intensifying insulin.
- Education addresses barriers, reduces treatment burden, and improves adherence.
- Optimized education and insulin therapy lead to better clinical outcomes.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...